JPWO2007102326A1 - アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導 - Google Patents

アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導 Download PDF

Info

Publication number
JPWO2007102326A1
JPWO2007102326A1 JP2008503780A JP2008503780A JPWO2007102326A1 JP WO2007102326 A1 JPWO2007102326 A1 JP WO2007102326A1 JP 2008503780 A JP2008503780 A JP 2008503780A JP 2008503780 A JP2008503780 A JP 2008503780A JP WO2007102326 A1 JPWO2007102326 A1 JP WO2007102326A1
Authority
JP
Japan
Prior art keywords
hiv
adenovirus type
gene
vector
structural gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503780A
Other languages
English (en)
Japanese (ja)
Inventor
奥田　研爾
研爾 奥田
島田　勝
勝 島田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yokohama City University
Original Assignee
Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yokohama City University filed Critical Yokohama City University
Publication of JPWO2007102326A1 publication Critical patent/JPWO2007102326A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008503780A 2006-03-07 2007-02-26 アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導 Pending JPWO2007102326A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006061007 2006-03-07
JP2006061007 2006-03-07
PCT/JP2007/053469 WO2007102326A1 (fr) 2006-03-07 2007-02-26 Induction d'une immunité forte au moyen d'une combinaison d'un vecteur d'adénovirus de type 5/type 35 et vecteur mva de virus vaccinal

Publications (1)

Publication Number Publication Date
JPWO2007102326A1 true JPWO2007102326A1 (ja) 2009-07-23

Family

ID=38474764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503780A Pending JPWO2007102326A1 (ja) 2006-03-07 2007-02-26 アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導

Country Status (3)

Country Link
JP (1) JPWO2007102326A1 (fr)
CN (1) CN101394868B (fr)
WO (1) WO2007102326A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
CN101781636A (zh) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
CN101670102A (zh) * 2009-09-15 2010-03-17 中国科学院广州生物医药与健康研究院 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506346A (ja) * 1997-06-09 2002-02-26 オクソン・ファーマクシンズ・リミテッド Ｃｄ８ ｔ細胞免疫応答を発生するワクチン接種のための方法および試薬
JP2004537974A (ja) * 2001-03-08 2004-12-24 アメリカ合衆国 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
WO2005052165A1 (fr) * 2003-11-28 2005-06-09 Aristo K.K. Vecteur d'adenovirus chimerique de type 5, 11 ou 35 utilise dans la prevention d'une infection par le virus de l'immunodeficience humaine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1490056A (zh) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506346A (ja) * 1997-06-09 2002-02-26 オクソン・ファーマクシンズ・リミテッド Ｃｄ８ ｔ細胞免疫応答を発生するワクチン接種のための方法および試薬
JP2004537974A (ja) * 2001-03-08 2004-12-24 アメリカ合衆国 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
WO2005052165A1 (fr) * 2003-11-28 2005-06-09 Aristo K.K. Vecteur d'adenovirus chimerique de type 5, 11 ou 35 utilise dans la prevention d'une infection par le virus de l'immunodeficience humaine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012014342; Ｇｅｎｅ Ｔｈｅｒａｐｙ Ｖｏｌ．１２, 2005, ｐ．１７６９-１７７７ *
JPN6012014344; Ｓｃｉｅｎｃｅ Ｖｏｌ．２９２, 2001, ｐ．６９-７４ *

Also Published As

Publication number Publication date
CN101394868B (zh) 2011-08-10
CN101394868A (zh) 2009-03-25
WO2007102326A1 (fr) 2007-09-13

Similar Documents

Publication Publication Date Title
US11896663B2 (en) Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
WO2012053646A1 (fr) Vecteur de virus pour des vaccins amorce/rappel, qui comprend un vecteur de virus de la vaccine et un vecteur de virus de sendai
CA2581840A1 (fr) Vaccins optimises pour obtenir une protection contre le virus ebola et autres virus
JP4125128B2 (ja) ヒト免疫不全ウイルスのキメラタンパク質用組換えポックスウイルス
JP2007532656A (ja) アデノウイルスベクターを用いて免疫応答を誘導するための方法
JP6612237B2 (ja) ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
EP2020444B1 (fr) Vecteurs lentivirus de transfert, déficient dans la function d'intégration, utilisés comme vaccins
JPWO2007102326A1 (ja) アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導
Bongard et al. Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors
Larke et al. Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen
AU2022386715A1 (en) Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
Wild et al. Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model
CN109923212B (zh) 用于表达乙肝病毒（hbv）抗原的慢病毒载体
JP2015520175A (ja) インターロイキン−４アンタゴニストを伴うワクチン接種
US12023377B2 (en) Vaccine for use in the prophylaxis and/or treatment of a disease
US20220347291A1 (en) Vaccine for use in the prophylaxis and/or treatment of a disease
RU2794196C2 (ru) Усилитель t-клеточного ответа на вакцину
US20220184202A1 (en) A recombinant htlv-1 vaccine
JP2010168288A (ja) 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
JP2024509976A (ja) 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター
JP2017512499A (ja) モザイクｈｉｖ−１配列およびその使用
WO2024023135A1 (fr) Vecteurs lentiviraux pour l'expression d'antigènes du papillomavirus humain (hpv) et leur mise en oeuvre dans le traitement de cancers induits par le hpv
Cecil et al. Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles
JP4914956B2 (ja) Ｄｎａワクチン

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121023